Jim Jin – VP & China General Manager, Gilead Sciences
Since first establishing an affiliate in China back in 2017, Gilead Sciences has been able to introduce 11 innovative medicines to the Chinese market – eight of which have been…
Address: Rongjing Dong Street, Beijing Economic and Technological Development Zone Zip: 100176
Tel: -111549.584415584
Web: http://www.biotechplc.com/
BioteQ Bio-Pharmaceutical Co., Ltd. was established in August 2000, China and Cuba in the field of biotechnology, the highest level, the largest investment cooperation projects, to research and development and production of the treatment of malignant tumors, the source resistance, monoclonal antibodies and vaccines undertake the major projects of the National High-Tech Research and Development Plan, the national high-tech industrialization demonstration project for the main direction.
100 Thai Biological Pharmaceutical has China’s first world-class antibodies humanized technology platform, represents a core technology of the international bio-pharmaceutical development and direction of the mainstream. The company designed and built the production line of China’s first fully automated large-scale mammalian cell culture, which is currently the largest, most comprehensive facilities, the most technologically advanced large-scale cell culture technology platform.
The Biological Pharmaceutical Baitai successfully developed China’s first personal humanized monoclonal antibody drug – Taixinsheng nimotuzumab the drug in April 2005 Biology I class drug certificate issued by the State Food and Drug Administration , fill our humanized monoclonal antibody drugs blank. The Taixinsheng ® can specifically target the tumor cells to targeted therapies in killing tumor cells without damaging normal tissue, and represent the latest developments in the direction of the field of cancer treatment. Clinical studies have shown that Taixinsheng ® single-agent or combined radiotherapy and chemotherapy for head and neck cancer, colorectal cancer, glioma, non-small cell lung cancer efficacy, significant side effects is low, with high clinical value.
Same time the Biological Pharmaceutical Baitai actively carry out international technical transformation, is committed to nurturing the capability of independent innovation, new drugs are being developed, including the EGF vaccine for the treatment of cancer, psoriasis and rheumatoid arthritis, a humanized anti-CD6 single anti for reversal of organ transplant rejection anti-CD3 mAb.
The Biological Pharmaceutical development Baitai target large modern biopharmaceutical company, to improve antibody drug research and development capabilities and production levels, to improve the health of the people for the purpose, internationalization, industrialization, standardization, the scale of the operation mode, is committed to the latest achievements of the development of biotechnology into the cause of the health of the 21st century, and continuous dedication to the community is the most advanced, most excellent antibody drugs, witnessed the rise of China’s life sciences and biomedicine with you!
Research and Development
Since first establishing an affiliate in China back in 2017, Gilead Sciences has been able to introduce 11 innovative medicines to the Chinese market – eight of which have been…
Jimmy Wei founded Chime Biologics over 12 years ago with the vision of establishing a global biologics company in China, focusing on biosimilar development and CDMO services. The company’s growth…
Boan Biotech CEO Jiang Hua outlines the Luye Pharma-acquired company’s approach, securing stable revenues through its biosimilars while pursuing novel platforms and innovative drug development. She provides insights into the…
Cytiva is a global leader in bioprocessing technologies and services that support the manufacturing and research of biopharmaceuticals. China is a key market in the company’s growth story, where –…
Unlike many of its Chinese biotech peers with broad portfolios, Hua Medicine has focused intensively on developing a single product, dorzagliatin, for diabetes. As CEO Li Chen notes, this strategic…
Yoshitaka Koketsu explains Sumitomo Pharma Group’s positioning in the China market as a relatively recent market entrant with a six-product portfolio but with plentiful opportunities for further growth, particularly in…
Global pharma has been stepping up M&A activity in Asia while also looking to access Asian markets through local partners and tap into the region’s huge growth potential. As a…
HKEX-main board listed Alphamab Oncology is one of China’s leading biotech success stories, having developed and marketed the world’s first subcutaneously injectable PD-L1 inhibitor. Founder, Chairman, and CEO Dr Xu…
Chinese player Legend Biotech reached a new turning point last month when its Johnson & Johnson-partnered Carvykti became the first BCMA-targeted CAR-T cell therapy to be approved by the FDA…
In recent years, global pharma’s Business Development (BD) operations in Asia have evolved from primarily managing global agreements locally to engaging in more complex tasks like contract negotiation and due…
Since it was established in 1988, PhIRDA, an organization that groups together China’s pharma innovators, research institutions and investors has played an active role in the evolution of China’s biopharma…
Han Yahui from Chinese folic acid specialist Scrianen outlines her company’s role in keeping mothers and newborns healthy in China, Scrianen’s approach to international partnerships, and the next horizons in…
See our Cookie Privacy Policy Here
